H.C. Wainwright raised the firm’s price target on Tango Therapeutics to $17 from $16 and keeps a Buy rating on the shares following the Q4 report. The firm says MRTX1719’s and AMG 193’s dose-escalation results mitigate the development risk for Tango’s TNG908 and TNG462.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNGX:
- Navigating the AI Minefield: Tango Therapeutics’ Struggle with Security Risks and EU Regulations
- Tango Therapeutics reports Q4 EPS (32c), consensus (28c)
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Rivian downgraded, Loweâs upgraded: Wall Street’s top analyst calls
- Tango Therapeutics initiated with an Overweight at Piper Sandler
